CCDC44 Activators
CCDC44 Activators encompass a diverse array of chemical compounds that synergistically enhance the functional activity of CCDC44 through modulation of specific signaling pathways and cellular processes. Forskolin, by augmenting intracellular cAMP levels, indirectly potentiates CCDC44's activity by catalyzing PKA activation, which can phosphorylate proteins within the pathways CCDC44 is known to operate. This cascade of events facilitates an enhancement of CCDC44's role, particularly if its function is contingent upon cAMP-responsive elements. Similarly, PMA activates PKC, which phosphorylates substrates that may interact with CCDC44, thus promoting its functional activity. The targeted influence of A23187 on intracellular calcium levels activates calcium-dependent kinases that might phosphorylate CCDC44 or its partners, leading to an enhanced biological activity of CCDC44. Sphingosine-1-phosphate, by binding to its receptors, can activate signaling pathways that modulate cellular functions involving CCDC44, while IBMX's inhibition of phosphodiesterases results in elevated cAMP and cGMP levels, indirectly augmenting CCDC44's activity through enhanced PKA and PKG activity.
Epigallocatechin gallate (EGCG), by inhibiting various protein kinases, potentially diminishes competitive signaling, thus allowing CCDC44's pathways to become more prominent. The PI3K inhibitors, LY294002 and Wortmannin, reduce the activity of the PI3K/Akt pathway, which could redirect signaling through pathways where CCDC44 is active, enhancing its role. Thapsigargin's inhibition of the SERCA pump leads to an increase in cytosolic calcium, which can amplify the activity of CCDC44 by activating calcium-dependent pathways. Genistein's inhibition of tyrosine kinases can similarly enhance CCDC44's activity by reducing competition from tyrosine kinase signaling. Lastly, the specific inhibitors of MAPK signaling, SB203580 and U0126, by inhibiting p38 and MEK1/2, respectively, might shift signaling toward pathways where CCDC44 is more active, thus promoting its function. Collectively, these CCDC44 Activators enhance the protein's function by influencing the pathways and cellular processes that CCDC44 is directly involved in, without the need for upregulating its expression or direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which is involved in various signaling pathways. Activation of PKC can lead to the phosphorylation of proteins that interact with CCDC44, thereby facilitating the enhancement of CCDC44's functional activity in its respective pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 selectively increases intracellular calcium levels. Elevated calcium can activate calcium-dependent protein kinases, which may phosphorylate CCDC44 or associated proteins, resulting in the enhancement of CCDC44's biological activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate is a bioactive lipid that can activate sphingosine-1-phosphate receptors, modulating intracellular signaling pathways such as those involving calcium mobilization. This activation can enhance CCDC44's activity by influencing proteins in its signaling network. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP and cGMP, which can enhance PKA and PKG activity. This, in turn, can lead to the activation of downstream proteins that interact with CCDC44, enhancing its functional role. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known for its ability to inhibit multiple protein kinases. This inhibition can decrease competitive signaling pathways, potentially allowing pathways where CCDC44 is involved to be more active, thus enhancing the function of CCDC44. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can shift cellular signaling dynamics towards pathways not dependent on PI3K/Akt signaling. This shift can potentially enhance the signaling pathways where CCDC44 is active, by reducing the regulatory effects of PI3K on these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that functions similarly to LY294002, and can modulate signaling networks such that the activity of CCDC44 is enhanced due to decreased PI3K/Akt pathway competition. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor which leads to increased cytosolic calcium levels, activating calcium-dependent signaling pathways. This can enhance the activity of CCDC44 if it is regulated by or interacts with proteins in calcium-dependent pathways. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can reduce phosphorylation on competitive signaling pathways. This reduction may enhance the pathways in which CCDC44 is active, by reducing negative regulation or competition, thus enhancing CCDC44's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK could lead to the enhancement of alternative signaling pathways, potentially including those where CCDC44 is active, by reducing the p38-mediated regulation of these pathways. | ||||||